Cargando…

Immunotherapy for head and neck squamous cell carcinoma

Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been rece...

Descripción completa

Detalles Bibliográficos
Autor principal: Fuereder, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923082/
https://www.ncbi.nlm.nih.gov/pubmed/27429658
http://dx.doi.org/10.1007/s12254-016-0270-8
_version_ 1782439679479513088
author Fuereder, Thorsten
author_facet Fuereder, Thorsten
author_sort Fuereder, Thorsten
collection PubMed
description Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved for the treatment of various malignancies and are currently being investigated in clinical phase III trials for head and neck squamous cell carcinoma (HNSCC). Data available from these trials indicate substantial activity accompanied by a favorable safety and toxicity profile in this patient population. This review article focuses on the molecular background, gives an overview of current clinical data of checkpoint inhibitors in HNSCC, and points out future challenges such as the need for appropriate biomarkers for these novel compounds.
format Online
Article
Text
id pubmed-4923082
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-49230822016-07-13 Immunotherapy for head and neck squamous cell carcinoma Fuereder, Thorsten Memo Short Review Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/programmed death ligand 1 (PD-1/PDL-1) and PDL-2, have been recently approved for the treatment of various malignancies and are currently being investigated in clinical phase III trials for head and neck squamous cell carcinoma (HNSCC). Data available from these trials indicate substantial activity accompanied by a favorable safety and toxicity profile in this patient population. This review article focuses on the molecular background, gives an overview of current clinical data of checkpoint inhibitors in HNSCC, and points out future challenges such as the need for appropriate biomarkers for these novel compounds. Springer Vienna 2016-06-20 2016 /pmc/articles/PMC4923082/ /pubmed/27429658 http://dx.doi.org/10.1007/s12254-016-0270-8 Text en © The Author(s) 2016 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Short Review
Fuereder, Thorsten
Immunotherapy for head and neck squamous cell carcinoma
title Immunotherapy for head and neck squamous cell carcinoma
title_full Immunotherapy for head and neck squamous cell carcinoma
title_fullStr Immunotherapy for head and neck squamous cell carcinoma
title_full_unstemmed Immunotherapy for head and neck squamous cell carcinoma
title_short Immunotherapy for head and neck squamous cell carcinoma
title_sort immunotherapy for head and neck squamous cell carcinoma
topic Short Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923082/
https://www.ncbi.nlm.nih.gov/pubmed/27429658
http://dx.doi.org/10.1007/s12254-016-0270-8
work_keys_str_mv AT fuerederthorsten immunotherapyforheadandnecksquamouscellcarcinoma